0 Responses Abattis News | Northern Vine


Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”) is pleased to announce the addition of Jaclyn Thomson, PhD, to our senior management team at Northern Vine Labs, and the appointment of Rene David to the Abattis Board of Directors. As the construction and buildout of Northern Vine Labs continues, more key management hires and appointments will accompany this next stage of growth.

Jaclyn will join the team and will be responsible for lab operations and testing protocols, while ensuring all transactions involving controlled substances comply with appropriate regulations and standards.

Jaclyn obtained her BSc. at the University of Victoria, and her PhD. in Organometallic Chemistry from the University of British Columbia. She brings a wide breadth of experience to the Company involving her previous positions in Quality Assurance, Scientific and Regulatory Consultation and Research. Jaclyn has years of experience in lab operations and is credited with publishing a highly successful academic manuscript regarding the extensive worldwide problem of Ginko Biloba adulteration in the journal Phytomedicine. Management feels confident that Jaclyn will be a key leader in Northern Vine’s efforts to test for licensed producers and patients under the ACMPR system.

“Her appointment is a critical component of our overall strategy to position Northern Vine as the leader in not only the testing of, but also the subsequent formulations and science behind the cannabis plant,” says Rene David, CFO of Abattis. “Jaclyn’s in-depth knowledge of GMP, as well as natural health products and Health Canada regulations, means Northern Vine will maintain consistency with its procedures and ensure safe and reliable results on every product tested.”

The shift of Mr. David from day-to-day operations into a position of oversight signals the lengthy preparations the Company has made to harness and sustain a focused growth trajectory. As CFO of Abattis, Mr. David has gained tremendous experience in the medical cannabis industry through working with Abattis and has been instrumental in guiding the Company’s strategic expansion.

Jim Irving, Director, welcomes Mr. David to the Board: “We are happy to have Rene join the Board. His experience as CFO and COO will provide us with valuable insight and practical solutions to move the Company forward in the dynamic legal cannabis and nutraceutical industries, in Canada and abroad.”

Mr. David has over 20 years of experience in real estate development, finance, and business strategy. He started his career at Vancity, Canada’s largest Credit Union, as a real estate developer and then went into investment banking in Western Canada. He later expanded his interests to include the resource, food and water industries, and assisting corporations who are dealing with the globalization of local resources. In his normal course of duties, Mr. David’s responsibilities include internal financial controls and analysis, procurement and contracts management. His continuous review of operating and capital plans is geared towards improving the internal controls and financial best practices in order to deliver the highest value product and strong company values.

Mr. David noted, “Since receiving our Health Canada Dealers License in September of 2016, we have narrowed our focus on key pillars for future growth; testing and analytics and product sales into international markets through its wholly owned subsidiary, Vergence Bioceuticals. As we prepare Northern Vine Labs for the next stage of operations, I felt it was appropriate to transition to the position of director and open up the leadership program to a greater level. A lot of hard work has been completed and I am excited to see what the Abattis team will bring as the Company moves into a stage of growth.”


Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.


Northern Vine LabsTM is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine LabsTM product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian market (www.northernvinelabs.com).


Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis Bioceuticals Corp. based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe, and effective natural products that meet unmet wellness needs.

Rene David
Rene David, CFO

For further information, contact the Company at (604) 336-0881, or at news@abattis.com.


This press release contains forward-looking statements. The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.


SOURCE: Abattis Bioceuticals Corp.

Leave a Reply

Your email address will not be published. Required fields are marked *